Buy Suven Pharmaceuticals; target of Rs 760: Anand Rathi

Anand Rathi is bullish on Suven Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 760 in its research report dated August 18, 2020.

Broker Research

August 20, 2020 / 14:03 IST

26 Aug, 2025 12:21

Volume

Todays L/H

Anand Rathi 's research report on Suven Pharmaceuticals

Strong, 39%, growth in its CDMO pharma to `1.3bn led to Suven’s Q1 FY21 sales rising 20.7% y/y to `2.4bn. The unfavourable product mix, however, pulled the gross margin down 875bps to 70.3%. But operating leverage helped curtail the EBITDA margin decline (down 486bps y/y) to 47%. On the lower share of profit from the Rising Pharma JV and the higher tax rate, PAT was flat at `915m. Suven is on track in launching molecules (two in specialty chemicals over FY21-22 and one in pharma) in CDMO and in filing formulation products (six pending approval, another five being developed). Traction in its CDMO business and steady formulation launches would drive 17.3%/19.2% growth in sales/ earnings over FY20-23.

Outlook

We retain our Buy recommendation with a higher target of `760 (earlier `695).

For all recommendations report, click here